ZHONGHENG GROUP(600252)2024-10-29 10:32Financial Performance - The company's operating revenue for Q3 2024 was ¥515,901,641, a decrease of 24.84% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥10,688,662.13, representing a decline of 133.19% year-on-year[2]. - The basic earnings per share for the current period was -¥0.0031, down 132.98% from the previous year[2]. - Total operating revenue for the first three quarters of 2024 was CNY 1,926,864,707.67, a decrease of 11.03% compared to CNY 2,165,747,164.01 in the same period of 2023[21]. - Net profit for the third quarter of 2024 was CNY -9,185,478.53, compared to a net profit of CNY 57,481,114.63 in the same quarter of 2023, indicating a significant decline[22]. - The total equity attributable to shareholders of the parent company was CNY 6,510,692,161.28, down from CNY 6,569,449,409.17 in the previous year[20]. - The company's basic and diluted earnings per share for Q3 2024 were both CNY 0.0033, down from CNY 0.0352 in Q3 2023, representing a decline of approximately 90.6%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥11,411,781,938.81, a decrease of 2.18% from the end of the previous year[3]. - The company's total assets were CNY 11,411,781,938.81 in Q3 2024, down from CNY 11,665,960,096.15 in Q3 2023, a decrease of approximately 2.17%[20]. - The company's total liabilities decreased to CNY 3,214,641,959.77 in Q3 2024 from CNY 3,389,145,978.87 in Q3 2023, a reduction of approximately 5.15%[20]. - The company's accounts receivable decreased from CNY 881,149,011.01 to CNY 586,686,664.76 during the same period[17]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥446,258,897.73, an increase of 15.49% year-on-year[2]. - The net cash flow from operating activities for the first three quarters of 2024 was CNY 446,258,897.73, up from CNY 386,392,102.83 in the same period of 2023, indicating a growth of about 15.5%[25]. - Cash inflows from operating activities totaled CNY 3,127,573,796.23 in Q3 2024, compared to CNY 2,944,560,847.39 in Q3 2023, reflecting an increase of approximately 6.2%[25]. - The net cash flow from financing activities for Q3 2024 was negative CNY 397,260,851.75, compared to negative CNY 221,095,496.14 in Q3 2023, indicating a worsening of approximately 79.8%[26]. - The total cash and cash equivalents at the end of Q3 2024 stood at CNY 3,458,763,556.53, down from CNY 3,718,418,480.61 at the end of Q3 2023, a decrease of about 7%[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 112,452[7]. - The largest shareholder, Guangxi Investment Group Co., Ltd., holds 24.90% of the shares, totaling 859,343,587 shares[8]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the top five alone accounting for over 75%[8]. - The company is actively engaging in share buybacks to enhance shareholder value and implement employee stock ownership plans[12]. Research and Development - The company's subsidiary Sichuan Yingrui Pharmaceutical Technology Co., Ltd. received ethical approval for the Phase II clinical trial of "Nano Carbon Iron Suspension Injection" in August 2024[14]. - Chongqing Laimei Pharmaceutical Co., Ltd. obtained a supplementary application approval notice for the drug "Cefoperazone Acetate Dry Suspension" (specification: 50mg), enhancing the company's product line[14]. - Research and development expenses for the first three quarters of 2024 were CNY 78,165,513.41, a decrease of 13.2% from CNY 89,986,838.54 in the same period of 2023[21]. Legal and Compliance - The company was ordered to pay CNY 21,648,313.00 to Changchun Haiyue Pharmaceutical Co., Ltd. as part of a legal dispute resolution[15]. - Chengdu Jinxing Health Pharmaceutical Co., Ltd. was awarded CNY 8,409,000.00 in a court ruling against Chengdu Yaoyun Pharmaceutical Technology Co., Ltd. for fund occupation[16].